



(12) **United States Patent**
Tamarkin et al.

(10) **Patent No.:** **US 6,274,552 B1**
(45) **Date of Patent:** **Aug. 14, 2001**

- (54) **COMPOSITION AND METHOD FOR DELIVERY OF BIOLOGICALLY-ACTIVE FACTORS**
- (75) Inventors: **Lawrence Tamarkin**, Rockville; **Guilio F. Paciotti**, Baltimore, both of MD (US)
- (73) Assignee: **CytImmune Sciences, Inc.**, College Park, MD (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: **08/966,940**
- (22) Filed: **Nov. 10, 1997**

Related U.S. Application Data

- (63) Continuation-in-part of application No. 08/795,962, filed on Feb. 6, 1997, now abandoned, which is a continuation of application No. 08/586,427, filed on Jan. 16, 1996, now abandoned, which is a continuation of application No. 08/215,030, filed on Mar. 18, 1994, now abandoned, which is a continuation-in-part of application No. 08/033,385, filed on Mar. 18, 1993, now abandoned.
- (51) **Int. Cl.**⁷ **A61K 38/00**
- (52) **U.S. Cl.** **514/12**; 514/2; 514/885; 530/350; 530/351; 424/617; 424/618; 424/649; 424/85.1
- (58) **Field of Search** 424/617, 618, 424/649, 85.1; 530/350, 351; 514/2, 12, 885

References Cited

U.S. PATENT DOCUMENTS

2,768,958	10/1956	Stewart et al.	252/313
2,785,153	3/1957	Locke et al.	260/114
3,145,144	8/1964	Ando	167/78
3,149,036	9/1964	Woodhour et al.	167/78
3,269,912	8/1966	Grase	167/78
3,399,263	8/1968	Strazdins et al.	424/88
3,531,565	9/1970	Webb et al.	424/92
3,577,523	5/1971	Stolar et al.	424/88
3,651,211	3/1972	Gillchriest et al.	424/89
3,819,820	6/1974	Lorina et al.	424/1
3,919,413	11/1975	Mebus	424/89
3,983,228	9/1976	Woodhour et al.	424/89
4,016,252	4/1977	Relyveld	424/88
4,053,587	10/1977	Davidson et al.	424/131
4,069,313	1/1978	Woodhour et al.	424/89
4,177,263	12/1979	Rosenberg et al.	424/131
4,196,185	4/1980	Focella et al.	424/1
4,197,237	4/1980	Leute et al.	260/112
4,197,286	4/1980	Rao	424/1
4,213,964	7/1980	Buckler	424/85
4,215,036	7/1980	Malley	260/112
4,218,436	8/1980	Fitzpatrick	424/85
4,329,281	5/1982	Christenson et al.	260/112
4,330,530	5/1982	Baker	424/131
4,332,787	6/1982	Homcy et al.	424/1
4,339,437	7/1982	Rosenberg et al.	424/131
4,346,074	8/1982	Gilmour et al.	424/92
4,451,570	5/1984	Royston et al.	435/240

4,487,780	12/1984	Scheinberg	424/294
4,578,270	3/1986	Csizer et al.	424/92
4,594,325	6/1986	Lundak	435/240
4,608,252	8/1986	Khanna et al.	424/85
4,624,921	11/1986	Larrick et al.	435/172.2
4,624,923	11/1986	Margel	435/176
4,639,336	1/1987	Jouquey et al.	260/397
4,657,763	4/1987	Finkelstein	424/131
4,693,975	9/1987	Kozbor et al.	435/172.2
4,720,459	1/1988	Winkelhake	435/240.2
4,740,589	4/1988	Moreno	530/395
4,744,760	5/1988	Molday	424/3
4,753,873	6/1988	Beltz et al.	435/5
4,812,556	3/1989	Vahlne et al.	530/324
4,880,750	11/1989	Francœur	436/501
4,882,423	11/1989	Taguchi et al.	530/380
4,906,564	3/1990	Lyon et al.	435/7
4,977,286	12/1990	Nicolaou et al.	552/4
5,017,687	5/1991	Vahlne et al.	530/324
5,019,497	5/1991	Olsson	435/7.23
5,035,995	7/1991	Taguchi et al.	435/4
5,112,606	5/1992	Shiosaka et al.	530/398.2
5,126,253	6/1992	Nakanishi et al.	435/70.21

FOREIGN PATENT DOCUMENTS

981242	1/1965	(DE) .
0 044 722	1/1982	(EP) .
0 156 242	12/1985	(EP) .
0 179 483	4/1986	(EP) .
0 269 408	11/1987	(EP) .
0 667 398	8/1995	(EP) .
2 334 366	7/1977	(FR) .
2 533 827	9/1982	(FR) .
WO 91 02078	2/1991	(WO) .
9421288 *	9/1994	(WO) .
WO 94/21288	9/1994	(WO) .
WO 96/04313	2/1996	(WO) .

OTHER PUBLICATIONS

Hopkins et al., "Early Events Following the Binding of Epidermal Growth Factor to Surface Receptors on Ovarian Granulosa Cells", *Eur. J. Cell Bio.*, vol. 24, pp. 259-265 (1981).

Primary Examiner—Dwayne C. Jones

Assistant Examiner—C. Delacroix-Muirheid

(74) *Attorney, Agent, or Firm*—Kilpatrick Stockton LLP

(57) **ABSTRACT**

In accordance with the present invention, a composition and method is provided that allows for the administration of a biologically-active factors to a human or animal. The present invention can be used to treat a disease with a biologically-active factor or combination of biologically-active factors, or can be used to safely vaccinate a human or animal against a biologically-active factor. It can also be used as a method for the delivery of biologically-active factors for the treatment of disease. Additionally, the present invention also includes a method of targeted drug delivery for the treatment of disease through the administration of custom complexes containing of one or more biologically active factors bound to a colloidal metal where at least one of the biologically-active factors is capable of binding a high affinity receptor on a cell surface.

21 Claims, 12 Drawing Sheets

(4 of 12 Drawing Sheet(s) Filed in Color)